Physician profile
Edward Panousieris
NPI 1578675864
$2,811.80
in general payments reported to CMS, 2019-2025
23 companies · $411 in 2025
The $411 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,400 · 2020: $82.38 · 2021: $206 · 2022: $250 · 2023: $251 · 2024: $212 · 2025: $411.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $874.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $874.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $526.37 | 2019-2025 | Breztri |
| Amarin Pharma, INC. | $468.62 | 2019-2021 | |
| Abbott Laboratories | $267.81 | 2019-2025 | Freestyle Libre 3 |
| Janssen Pharmaceuticals, INC | $245.95 | 2019-2020 | |
| Novo Nordisk INC | $226.53 | 2021-2025 | Ozempic |
| Abbvie INC. | $216.47 | 2021-2025 | |
| Idorsia Pharmaceuticals US INC | $165.04 | 2022-2023 | Quviviq |
| Teva Pharmaceuticals USA, INC. | $136.38 | 2019 | |
| Lilly USA, LLC | $116.39 | 2023 | Mounjaro |
| Medtronic Vascular, INC. | $75.81 | 2019 | |
| Shire North American Group INC | $52.80 | 2019 | |
| Exact Sciences Corporation | $47.31 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Corcept Therapeutics | $41.68 | 2025 | Korlym |
| Amgen INC. | $33.65 | 2025 | Otezla, Repatha |
| Pfizer INC. | $32.12 | 2021-2023 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $27.60 | 2020 | |
| Dexcom, INC. | $25.94 | 2024 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.61 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $17.82 | 2019 | |
| Phadia US INC. | $17.35 | 2021 | |
| Glaxosmithkline, LLC. | $16.90 | 2023 | Trelegy Ellipta |
| Allergan, INC. | $15.12 | 2019 | |
| Novartis Pharmaceuticals Corporation | $14.53 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Panousieris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.